Carsten Denkert

69.2k total citations · 12 hit papers
522 papers, 29.5k citations indexed

About

Carsten Denkert is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Carsten Denkert has authored 522 papers receiving a total of 29.5k indexed citations (citations by other indexed papers that have themselves been cited), including 312 papers in Oncology, 254 papers in Cancer Research and 151 papers in Molecular Biology. Recurrent topics in Carsten Denkert's work include Breast Cancer Treatment Studies (146 papers), HER2/EGFR in Cancer Research (95 papers) and Cancer Genomics and Diagnostics (86 papers). Carsten Denkert is often cited by papers focused on Breast Cancer Treatment Studies (146 papers), HER2/EGFR in Cancer Research (95 papers) and Cancer Genomics and Diagnostics (86 papers). Carsten Denkert collaborates with scholars based in Germany, United States and Belgium. Carsten Denkert's co-authors include Jan Budczies, Manfred Dietel, Sibylle Loibl, Wilko Weichert, Gϋnter von Minckwitz, Balázs Győrffy, Silvia Darb‐Esfahani, András Lánczky, Qiyuan Li and Aron C. Eklund and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Carsten Denkert

503 papers receiving 29.1k citations

Hit Papers

An online survival analys... 2009 2026 2014 2020 2009 2012 2009 2021 2014 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
    2009 2.2k citations Carsten Denkert, Jan Budczies et al. profile →
  2. Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
    2012 1.8k citations Gϋnter von Minckwitz, Michael Untch et al. profile →
  3. Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
    2009 1.3k citations Carsten Denkert, Sibylle Loibl et al. profile →
  4. Breast cancer
    2021 1.0k citations Sibylle Loibl, Carsten Denkert et al. profile →
  5. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
    2014 956 citations Sibylle Loibl, Carsten Denkert et al. Annals of Oncology profile →
  6. Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization
    2012 954 citations Jan Budczies, Frederick Klauschen et al. profile →
  7. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
    2016 659 citations Carsten Denkert, Gϋnter von Minckwitz et al. profile →
  8. Clinical relevance of host immunity in breast cancer: from TILs to the clinic
    2015 638 citations Carsten Denkert et al. profile →
  9. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
    2019 438 citations Sibylle Loibl, Carsten Denkert et al. Annals of Oncology profile →
  10. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
    2015 432 citations Carsten Denkert, Holger Eidtmann et al. profile →
  11. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
    2022 136 citations Sibylle Loibl, Andreas Schneeweiß et al. Annals of Oncology profile →
  12. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
    2024 47 citations Lajos Pusztai, Carsten Denkert et al. Annals of Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Carsten Denkert 15.3k 11.5k 11.3k 4.4k 3.9k 522 29.5k
Stephen B. Fox 13.0k 0.9× 14.2k 1.2× 10.4k 0.9× 4.7k 1.1× 3.1k 0.8× 423 29.3k
Christos Sotiriou 15.6k 1.0× 12.3k 1.1× 13.8k 1.2× 4.4k 1.0× 3.2k 0.8× 366 29.1k
Jonas Bergh 15.6k 1.0× 11.2k 1.0× 11.6k 1.0× 4.9k 1.1× 2.1k 0.5× 521 29.1k
Lajos Pusztai 20.1k 1.3× 12.1k 1.1× 16.9k 1.5× 5.7k 1.3× 3.0k 0.8× 591 35.0k
Charles Swanton 12.8k 0.8× 13.0k 1.1× 12.7k 1.1× 8.5k 1.9× 2.9k 0.7× 325 30.6k
Lars A. Akslen 14.0k 0.9× 13.8k 1.2× 11.6k 1.0× 4.4k 1.0× 2.0k 0.5× 314 29.1k
Roger E. McLendon 12.9k 0.8× 19.5k 1.7× 11.8k 1.0× 5.3k 1.2× 5.3k 1.4× 330 42.0k
Joel S. Parker 11.4k 0.7× 16.2k 1.4× 13.2k 1.2× 4.3k 1.0× 2.3k 0.6× 278 29.7k
Torsten O. Nielsen 16.1k 1.0× 10.3k 0.9× 14.5k 1.3× 7.7k 1.8× 2.0k 0.5× 241 31.1k
Ana M. González-Angulo 15.2k 1.0× 8.9k 0.8× 11.4k 1.0× 5.2k 1.2× 1.6k 0.4× 281 25.2k

Countries citing papers authored by Carsten Denkert

Since Specialization
Citations

This map shows the geographic impact of Carsten Denkert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carsten Denkert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carsten Denkert more than expected).

Fields of papers citing papers by Carsten Denkert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carsten Denkert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carsten Denkert. The network helps show where Carsten Denkert may publish in the future.

Co-authorship network of co-authors of Carsten Denkert

This figure shows the co-authorship network connecting the top 25 collaborators of Carsten Denkert. A scholar is included among the top collaborators of Carsten Denkert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carsten Denkert. Carsten Denkert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Pusztai, Lajos, Carsten Denkert, Joyce O’Shaughnessy, et al.. (2024). Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Annals of Oncology. 35(5). 429–436. 47 indexed citations breakdown →
2.
Teply‐Szymanski, Julia, Ramona Erber, Annette Lebeau, et al.. (2023). Klinisch relevante molekularpathologische Diagnostik beim Mammakarzinom. PubMed. 44(1). 39–49. 2 indexed citations
3.
Schmid, Peter, Javier Cortés, Rebecca Dent, et al.. (2023). LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study. Annals of Oncology. 34. S1257–S1257. 20 indexed citations
4.
Ihlow, Jana, Inga Hoffmann, Philip Bischoff, et al.. (2022). Low Expression of RGS2 Promotes Poor Prognosis in High-Grade Serous Ovarian Cancer. Cancers. 14(19). 4620–4620. 8 indexed citations
5.
Silva, Miguel G., Björn Konukiewitz, Katja Steiger, et al.. (2021). Loss of SATB2 Occurs More Frequently Than CDX2 Loss in Colorectal Carcinoma and Identifies Particularly Aggressive Cancers in High-Risk Subgroups. Cancers. 13(24). 6177–6177. 13 indexed citations
6.
Priedigkeit, Nolan, Kai Ding, William Horne, et al.. (2021). Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences. Breast Cancer Research. 23(1). 1–1. 24 indexed citations
7.
Schneeweiß, Andreas, Sabine Seiler, Hans Tesch, et al.. (2020). Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial. Journal of the American Heart Association. 9(23). e018143–e018143. 26 indexed citations
8.
Loibl, Sibylle, Karsten E. Weber, Jens Huober, et al.. (2018). Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clinical Cancer Research. 24(14). 3358–3365. 8 indexed citations
9.
Basudan, Ahmed, Nolan Priedigkeit, Ryan J. Hartmaier, et al.. (2018). Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Molecular Cancer Research. 17(2). 457–468. 24 indexed citations
10.
Muckenhuber, Alexander, Anne Berger, Anna Melissa Schlitter, et al.. (2017). Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Clinical Cancer Research. 24(2). 351–359. 61 indexed citations
11.
Pfarr, Nicole, Silvia Darb‐Esfahani, Jonas Leichsenring, et al.. (2017). Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. Genes Chromosomes and Cancer. 56(10). 758–766. 16 indexed citations
12.
Hilvo, Mika, Inês de Santiago, Peddinti Gopalacharyulu, et al.. (2016). Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. Cancer Research. 76(4). 796–804. 70 indexed citations
13.
Loibl, Sibylle, Silvia Darb‐Esfahani, Jens Huober, et al.. (2016). Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clinical Cancer Research. 22(11). 2675–2683. 34 indexed citations
14.
Budczies, Jan, Moritz von Winterfeld, Frederick Klauschen, et al.. (2014). Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer. Journal of Clinical Pathology. 67(6). 482–490. 13 indexed citations
15.
Klauschen, Frederick, Stephan Wienert, Wolfgang Schmitt, et al.. (2014). Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study. Clinical Cancer Research. 21(16). 3651–3657. 78 indexed citations
16.
Jerby, Livnat, Lior Wolf, Carsten Denkert, et al.. (2012). Metabolic Associations of Reduced Proliferation and Oxidative Stress in Advanced Breast Cancer. Cancer Research. 72(22). 5712–5720. 107 indexed citations
17.
Böhnke, Anja, Eleonora Leucci, Søren Jensby Nielsen, et al.. (2010). An Illegitimate microRNA Target Site within the 3′ UTR of MDM4 Affects Ovarian Cancer Progression and Chemosensitivity. Cancer Research. 70(23). 9641–9649. 141 indexed citations
18.
Eckstein, Niels, Kati Servan, Barbara Hildebrandt, et al.. (2009). Hyperactivation of the Insulin-like Growth Factor Receptor I Signaling Pathway Is an Essential Event for Cisplatin Resistance of Ovarian Cancer Cells. Cancer Research. 69(7). 2996–3003. 134 indexed citations
19.
Weichert, Wilko, A.-E. Roske, Silvia Niesporek, et al.. (2008). Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo. Clinical Cancer Research. 14(6). 1669–1677. 299 indexed citations
20.
Denkert, Carsten, Jan Budczies, Tobias Kind, et al.. (2006). Mass Spectrometry–Based Metabolic Profiling Reveals Different Metabolite Patterns in Invasive Ovarian Carcinomas and Ovarian Borderline Tumors. Cancer Research. 66(22). 10795–10804. 304 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephen B. Fox Breakdown of academic impact, for papers by Christos Sotiriou Breakdown of academic impact, for papers by Jonas Bergh Breakdown of academic impact, for papers by Lajos Pusztai Breakdown of academic impact, for papers by Charles Swanton Breakdown of academic impact, for papers by Lars A. Akslen Breakdown of academic impact, for papers by Roger E. McLendon Breakdown of academic impact, for papers by Joel S. Parker Breakdown of academic impact, for papers by Torsten O. Nielsen Breakdown of academic impact, for papers by Ana M. González-Angulo
Rankless by CCL
2026